Advancements in Biopolymeric Materials for Biomedical Applications

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".

Deadline for manuscript submissions: closed (30 September 2023) | Viewed by 1459

Special Issue Editor


E-Mail Website
Guest Editor
LaMInFE-Laboratory of Industrial Microbiology and Fermentation Process, University of Sorocaba, Sorocaba 18023-000, SP, Brazil
Interests: bacterial cellulose; biomolecules; biopolymer; nanomaterial; industrial microbiology

Special Issue Information

Dear Colleagues,

Biopolymeric materials are divided into natural biopolymers, which include chitosan, cellulose, and gelatin, and industrial or synthetic polymers, which include polyethylene, polyester, Teflon, and others. This kind of materials are versatile and can be applied in food and biomedical areas. These emerging applications have evolved due to the preparation of based-nanomaterials with physicochemical and biological properties and which can be applied by modulating the diffusion of the drugs through the skin to assemble functional constructs that restore, maintain, or improve damaged tissues.

For this reason, this Special Issue is aimed at revising the state of the art and current trends of biopolymeric materials for biomedical applications, specifically those designed for improving tissue engineering, dental composites, and wound dressings.

If you work with any related keywords or topics, this Special Issue, "Advancements in Biopolymeric Materials for Biomedical Applications", is a place for you to publish your latest results on cutting-edge developments to encourage further advances in the field of biopolymeric materials. You may submit reviews and research papers. I am deeply honored to serve as Guest Editor of this Special Issue and look forward to the publications.

Dr. Angela Faustino Jozala
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • based-nanomaterials
  • biomolecules
  • biopolymer
  • nanomaterial
  • wound dressing
  • dental composites
  • tissue engineering
  • polymeric material

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

23 pages, 6009 KiB  
Article
Subconjunctival Delivery of Sorafenib-Tosylate-Loaded Cubosomes for Facilitated Diabetic Retinopathy Treatment: Formulation Development, Evaluation, Pharmacokinetic and Pharmacodynamic (PKPD) Studies
by Sharadha Madhusudhan, Naresh Vishal Gupta, Mohamed Rahamathulla, Saravana Babu Chidambaram, Riyaz Ali M. Osmani, Mohammed Ghazwani, Mohammed Muqtader Ahmed, Syeda Ayesha Farhana, Mohammed Y. Sarhan and Ahmed Hediyal Tousif
Pharmaceutics 2023, 15(10), 2419; https://doi.org/10.3390/pharmaceutics15102419 - 04 Oct 2023
Viewed by 1202
Abstract
Diabetic retinopathy (DR) is a microvascular complication associated with vascular endothelial growth factor (VEGF) overexpression. Therapeutic delivery to the retina is a challenging phenomenon due to ocular biological barriers. Sorafenib tosylate (ST) is a lipophilic drug with low molecular weight, making it ineffective [...] Read more.
Diabetic retinopathy (DR) is a microvascular complication associated with vascular endothelial growth factor (VEGF) overexpression. Therapeutic delivery to the retina is a challenging phenomenon due to ocular biological barriers. Sorafenib tosylate (ST) is a lipophilic drug with low molecular weight, making it ineffective at bypassing the blood–retinal barrier (BRB) to reach the target site. Cubosomes are potential nanocarriers for encapsulating and releasing such drugs in a sustained manner. The present research aimed to compare the effects of sorafenib-tosylate-loaded cubosome nanocarriers (ST-CUBs) and a sorafenib tosylate suspension (ST-Suspension) via subconjunctival route in an experimental DR model. In this research, ST-CUBs were prepared using the melt dispersion emulsification technique. The distribution of prepared nanoparticles into the posterior eye segments was studied with confocal microscopy. The ST-CUBs were introduced into rats’ left eye via subconjunctival injection (SCJ) and compared with ST-Suspension to estimate the single-dose pharmacokinetic profile. Streptozotocin (STZ)-induced diabetic albino rats were treated with ST-CUBs and ST-Suspension through the SCJ route once a week for 28 days to measure the inhibitory effect of ST on the diabetic retina using histopathology and immunohistochemistry (IHC) examinations. Confocal microscopy and pharmacokinetic studies showed an improved concentration of ST from ST-CUBs in the retina. In the DR model, ST-CUB treatment using the SCJ route exhibited decreased expression levels of VEGF, pro-inflammatory cytokines, and adhesion molecules compared to ST-Suspension. From the noted research findings, it was concluded that the CUBs potentially enhanced the ST bioavailability. The study outcomes established that the developed nanocarriers were ideal for delivering the ST-CUBs via the SCJ route to target the retina for facilitated DR management. Full article
(This article belongs to the Special Issue Advancements in Biopolymeric Materials for Biomedical Applications)
Show Figures

Figure 1

Back to TopTop